Side-by-side · Research reference

LiraglutidevsMatrixyl

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedFlagship14/45 cited

BAnimal-MechanisticHUMAN-REVIEWED9/39 cited

Liraglutide

Daily GLP-1 RA · FDA-Approved

0.6–3.0 mgDaily doseSAXENDA (liraglutide) injectio 2014

5–10%Body-weight ↓SAXENDA (liraglutide) injectio 2014

~13 hrHalf-lifeSAXENDA (liraglutide) injectio 2014

SQ · Abdomen / thigh / arm · Once daily

Matrixyl

Cosmeceutical Pentapeptide · Topical Anti-Aging

TopicalRoute

5-AALength (KTTKS)Gomes 2022

Collagen I/IIIPrimary targetPaccola 2025

Topical · Dermal · Twice Daily

01Mechanism of Action

Parameter

Liraglutide

Matrixyl

Primary target

GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014

Dermal fibroblastsPaccola 2025

Pathway

GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014 Marso 2016

Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling

Downstream effect

Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016

Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

—

Origin

Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014

Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022

Antibody development

—

02Dosage Protocols

Parameter

Liraglutide

Matrixyl

Standard dose (T2D, Victoza)

1.2–1.8 mg / daySAXENDA (liraglutide) injectio 2014

—

Standard dose (weight, Saxenda)

3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014

—

Frequency

Once daily, same time each day

—

Titration schedule

0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks

Mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016 SAXENDA (liraglutide) injectio 2014

—

Duration

Indefinite for chronic indication

8–12 weeks minimum for visible effect

Collagen synthesis requires sustained application.

Reconstitution

Pre-filled commercial pen (no reconstitution)

—

Timing

Any time of day; consistent

—

Half-life

~13 hrSAXENDA (liraglutide) injectio 2014

—

Formulation concentration

—

0.5–5% in topical vehicle

Common cosmeceutical range; higher concentrations in clinical formulations.

Application frequency

—

Twice daily (AM/PM)

Standard cosmeceutical protocol.

In vitro evidence

—

Fibroblast viability + ECM gene upregulationPaccola 2025

Vehicle

—

Serum, cream, or emulsion base

Lipophilic carriers enhance penetration.

04Side Effects & Safety

Parameter

Liraglutide

Matrixyl

GI symptoms

Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014

—

Pancreatitis risk

Rare; discontinue if suspected

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014

—

Hypoglycemia

Low risk as monotherapy; elevated with sulfonylureas / insulin

—

Heart rate

Modest ↑ resting HR (~2-3 bpm)

—

Cardiovascular benefit

↓ MACE in high-risk T2D (LEADER trial)Marso 2016

—

Pregnancy / OB

Contraindicated

—

Irritation

—

Mild erythema, pruritus in sensitive skin (rare)

Allergic reaction

—

Contact dermatitis (uncommon)

Systemic absorption

—

Negligible — topical application only

Absolute Contraindications

Liraglutide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to liraglutide

Matrixyl

·Known hypersensitivity to palmitoyl peptides

Relative Contraindications

Liraglutide

·Severe gastroparesis
·History of pancreatitis
·Severe gastrointestinal disease

Matrixyl

·Active dermatitis or open wounds at application site

05Administration Protocol

Parameter

Liraglutide

Matrixyl

1. Reconstitution / device

Commercial pre-filled pen, no reconstitution required.

Wash face with gentle cleanser. Pat dry.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate sites.

Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.

3. Timing

Once daily, same time each day. Take with or without food.

Twice daily — morning and evening. Apply before heavier creams or sunscreen.

4. Storage

Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.

Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.

5. Needle

Pen-supplied 32G needle.

—

06Stack Synergy

Liraglutide

— no documented stacks

Matrixyl

+ GHK-Cu

Multi-pathway

View GHK-Cu →

Matrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.

Matrixyl: 0.5–5% topical serum · AM/PM
GHK-Cu: 1–2% topical serum · same application
Frequency: Twice daily
Primary benefit: Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity